Search clinical trials for: phosphoinositide-3 kinase (PI3K)

Total 25967 results

Kazia Therapeutics Limited
Quotient Sciences

Completed

Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

Healthy

United Kingdom
Children's Hospital of Fudan University

Recruiting

Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome

Activated PI3K-delta Syndrome | Immunodeficiency Primary

China
Rhizen Pharmaceuticals SA

Completed

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies (PI3K)

Lymphoma, B-Cell | T-Cell Lymphoma

France, Italy
Shanghai Jiatan Pharmatech Co., Ltd

Completed

A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma

Advanced Cancer

China
Rhizen Pharmaceuticals SA

Withdrawn

Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

Peripheral T Cell Lymphoma

United States
AstraZeneca
Parexel

Completed

A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants.

Asthma

Germany
Rhizen Pharmaceuticals SA

Completed

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral

United States
AbbVie
Infinity Pharmaceuticals, Inc.

Completed

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

Lymphoma

Japan
Rhizen Pharmaceuticals SA

Completed

To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers

Healthy

Canada
Rhizen Pharmaceuticals SA

Completed

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Georgia, Bulgaria, Poland
Rhizen Pharmaceuticals SA

Completed

Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Georgia
Rhizen Pharmaceuticals SA

Completed

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Non Hodgkin Lymphoma

United States, Australia
German Breast Group
Roche Pharma AG

Recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (GeparPiPPa)

HER2-positive Breast Cancer

Germany
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Ductal Breast Carcinoma

United States
PIQUR Therapeutics AG
Charite University, Berlin, Germany; University Hospital, Basel, Switzerland; University Hospital Freiburg and other collaborators

Completed

Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

Lymphoma | Non-Hodgkin Lymphoma

Germany
M.D. Anderson Cancer Center

Terminated

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Advanced Cancers

United States
PIQUR Therapeutics AG
Royal Marsden NHS Foundation Trust; University College London Hospitals; Weill... and other collaborators

Completed

Open-Label, Non Randomized Phase 2 Study With Safety Run-In

Lymphoma, Malignant

United States, United Kingdom, Serbia, Bosnia and Herzegovina, France, Israel
GlaxoSmithKline

Terminated

Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma

Solid Tumours

United States
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Unknown

A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma
University of California, San Francisco
Novartis Pharmaceuticals; Pediatric Brain Tumor Foundation; The Lilabean Foundation...

Recruiting

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

High Grade Glioma | Low-grade Glioma | Recurrent World Health Organization (WHO) Grade II Glioma

United States
GlaxoSmithKline

Completed

Dose-Escalation Study of GSK2126458 (FTIH)

Solid Tumours

United States, Netherlands
Peter MacCallum Cancer Centre, Australia
Novartis Pharmaceuticals

Completed

Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer (PIKNIC)

Metastatic Breast Cancer

Australia
SecuraBio

Completed

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Belgium, France, Italy, Spain, United States, Austria, New Zealand, Hungary, Germany, United Kingdom, Australia
SecuraBio

Completed

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Belgium, France, Italy, Spain, United States, Austria, New Zealand, Hungary, United Kingdom, Australia, Germany
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | B-Cell Non-Hodgkin Lymphomas(NHL)

China
AstraZeneca
Parexel

Terminated

Evaluation of AZD8154 Concentrations in Blood

Asthma

Germany
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Unknown

Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma

Follicular Lymphoma(FL) | Marginal Zone Lymphoma(MZL)

China
Celcuity, Inc.

Completed

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Breast Cancer

United States
University of Arizona
National Cancer Institute (NCI)

Terminated

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

HPV Positive Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | CDKN2A-p16 Positive | Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7 | Stage II Oropharyngeal Squamous Cell Carcinoma...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Novartis Pharmaceuticals

Completed

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet)

Advanced or Metastatic Breast Cancer

Spain, United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Recurrent Non-Hodgkin Lymphoma

United States
Novartis Pharmaceuticals

Completed

BKM120 for Patients With PI3K-activated Tumors (SIGNATURE)

PI3K Pathway Activated Tumors

United States
SecuraBio

Terminated

Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R)

Follicular Lymphoma

France, Italy, Australia, Poland
Gilead Sciences

Terminated

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Bayer

Completed

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Neoplasms

United States
Incyte Corporation

Completed

A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

Autoimmune Hemolytic Anemia

United States, France, Italy, Austria
Northwestern University
National Cancer Institute (NCI); Novartis

Completed

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
Dana-Farber Cancer Institute
Gilead Sciences

Terminated

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Rhizen Pharmaceuticals SA

Completed

Compassionate Use Study of Tenalisib (RP6530)

Hematological Malignancies

United States, Georgia, Poland
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

CVL237 Tablets for APDS/PASLI

PI3K and P110delta Hyperactivation Syndrome

China
Rhizen Pharmaceuticals SA
Incozen Therapeutics Pvt Ltd

Recruiting

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer (TNBC)

India
Incyte Corporation

Completed

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

United States
Shanghai Changzheng Hospital

Completed

The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway

Colorectal Disease

China
GlaxoSmithKline

Completed

Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI

Activated PI3K-delta Syndrome

United Kingdom
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor ((CITADEL-205))

Lymphoma

United States, Spain, France, United Kingdom, Czechia, Israel, Belgium, Italy, Germany, Poland, Denmark
Pamela Munster
Novartis

Withdrawn

Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Solid Tumors, Adult | HPV-Related Squamous Cell Carcinoma | Human Papillomavirus-Related Carcinoma | PIK3CA Mutation-Related Tumors | PIK3CA Mutation | Human Papillomavirus-Related Squamous Cell Carcinoma

United States
Institute of Hematology & Blood Diseases Hospital...
YL-Pharma

Recruiting

Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Relapsed/Refractory Large Granular T Lymphocytic Leukemia

China
Incyte Corporation

Completed

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Lymphoma

Spain, Hungary, United States, Denmark, Italy, Czechia
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Lymphoma

United States, Spain, Italy, Israel, Poland, United Kingdom, Canada, Czechia, Germany, Denmark, Australia, Hungary, Sweden

Search clinical trials for: phosphoinositide-3 kinase (PI3K)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations